New drug combo aims to improve head and neck cancer outcomes

NCT ID NCT05366166

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether adding two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can help control locally advanced head and neck cancer. About 45 adults with this cancer will receive the drug combination. The main goal is to see if this approach improves the time people live without their cancer growing back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV-ASSOCIATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma human papillomavirus-related squamous cell carcinoma hypopharynx squamous cell carcinoma laryngeal squamous cell carcinoma oral cavity squamous cell carcinoma oropharynx squamous cell carcinoma squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Indiana University Simon Comprehensive Cancer Center

    Indianapolis, Indiana, 46202, United States

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina, 29425, United States

  • UNC Lineberger

    Chapel Hill, North Carolina, 27514, United States

  • University of Louisville, Brown Cancer Center

    Louisville, Kentucky, 40202, United States